Doses studied
Ipamorelin dosage, as the research recorded it — by species, route, and study.
What was administered to which model at which dose, plus the ~2-hour human half-life. Not a protocol, and not advice.
Read this first
This page describes ipamorelin dosage the way the published research describes it — what was given to rats, pigs, ferrets, and a small number of human volunteers, at what dose and by what route. It is not a protocol and it is not advice. There is no approved human dose of ipamorelin, because it was never approved as a medicine [3]. The one solid human dosing fact is how long it lasts: about a 2-hour terminal half-life after intravenous dosing, with the growth-hormone pulse peaking around 40 minutes in [2]. Everything else below is study context. Where you see community 'stack' regimens mentioned, treat them as exactly that — unverified anecdote with no peer-reviewed human dosing basis behind them.
Doses used in published studies
The published ipamorelin doses span a wide range across species and routes. In the human pharmacokinetic study, single IV infusions of 4.21–140.45 nmol/kg were given over 15 minutes [2]. In the human Phase 2 ileus trial, the dose was 0.03 mg/kg IV twice daily for up to seven days [3]. In the rat bone-growth study, ipamorelin was given subcutaneously at 18, 90, and 450 µg/day, divided three times daily [4]. The 2024 ferret cachexia study used 1–3 mg/kg intraperitoneally [5]. These figures are reported as study parameters, not as a guide — they cross species, routes, and purposes, and none translates to a human regimen.
Routes studied
Several routes appear in the literature. Intravenous dosing was used in the human pharmacokinetic and clinical work and in rodent efficacy studies [2][3]. Subcutaneous dosing dominated the rodent bone and body-composition studies [4] and is also the route most common in off-label community use — though that subcutaneous self-administration route has no published human safety or pharmacokinetic characterisation. Intraperitoneal dosing was used in the rodent and ferret efficacy studies [5]. Intranasal and oral routes appear only for engineered ipamorelin-derived analogs; ipamorelin itself is not orally bioavailable. The route a compound is studied by matters: a 2-hour IV half-life does not tell you how a subcutaneous injection behaves in a person, because that was never measured.
Half-life and pharmacokinetics
Ipamorelin's terminal half-life is approximately 2 hours in healthy human volunteers given it intravenously, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response it provokes is a single discrete pulse peaking at about 40 minutes (0.67 h) post-dose, not a sustained elevation [2]. In rats, plasma clearance is roughly five-fold lower than that of GHRP-6. The practical implication of a short half-life and a discrete pulse is that the GH signal is brief and self-limiting — which is part of why the compound was studied as a pulse-generator rather than a continuous GH source.
Handling and reconstitution notes
Ipamorelin is supplied as a lyophilized (freeze-dried) powder — free base or acetate salt — and reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw cycles, and reconstituted solution is typically kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature, not a clinical preparation instruction. Nothing here describes how a person should prepare or use the compound — only how the material behaves as a laboratory reagent.
How to reconstitute cjc-1295 ipamorelin 5mg
The question 'how to reconstitute cjc-1295 ipamorelin 5mg' comes up constantly in community forums, and the honest answer is that there is no validated human reconstitution or dosing protocol to point to. In general research-supply terms, lyophilized peptides are reconstituted with bacteriostatic water and kept refrigerated, degrading with heat and freeze-thaw — but the specific milligram-per-millilitre preparations shared online for combined CJC-1295/ipamorelin products carry no peer-reviewed human basis [3]. This site describes what the published studies administered (for ipamorelin: IV and subcutaneous doses in the references above) and does not provide preparation or dosing instructions for personal use.
How much cjc-1295 ipamorelin should i take
There is no answer to 'how much cjc-1295 ipamorelin should i take' that this site can responsibly give, because no controlled human trial has established a dose for the combination — or for ipamorelin alone for any body-composition use [3]. The only human ipamorelin doses on record are research doses: IV infusions in a pharmacokinetic study [2] and 0.03 mg/kg IV twice daily in the failed ileus trial [3]. Community subcutaneous 'stack' regimens exist, but they have no peer-reviewed human dosing basis and are anecdotal, not recommended. We describe what was studied; we do not tell anyone how much to take.